NCT01211457View on ClinicalTrials.gov

Study of Sapacitabine in Acute Myeloid Leukemia (AML) or Myelodysplastic Syndromes (MDS)

PHASE1/PHASE2UnknownINTERVENTIONAL
Enrollment

65

Participants

Timeline

Start Date

June 17, 2010

Primary Completion Date

June 20, 2020

Study Completion Date

December 31, 2020

Conditions
Acute Myeloid LeukemiaMyelodysplastic Syndromes
Interventions
DRUG

sapacitabine and decitabine (Part 1 - completed)

decitabine will be administered in alternating cycles with sapacitabine

DRUG

sapacitabine and venetoclax (Part 2 - recruiting)

sapacitabine will be administered concomitantly with venetoclax

Trial Locations (3)

14263

COMPLETED

Roswell Park Cancer Institute, Buffalo

60612

COMPLETED

Rush University Medical Center, Chicago

77030-3387

RECRUITING

MD Anderson Cancer Center, Houston

Sponsors
All Listed Sponsors
collaborator

M.D. Anderson Cancer Center

OTHER

lead

Cyclacel Pharmaceuticals, Inc.

INDUSTRY

NCT01211457 - Study of Sapacitabine in Acute Myeloid Leukemia (AML) or Myelodysplastic Syndromes (MDS) | Biotech Hunter | Biotech Hunter